A novel androgen‐reduced prostate‐specific lncRNA, PSLNR, inhibits prostate‐cancer progression in part by regulating the p53‐dependent pathway

Abstract

Our study revealed for the first time a novel androgen-reduced prostate-specific lncRNA, PSLNR, which inhibited PCa progression via the p53-dependent pathway, suggesting that PSLNR may be a candidate diagnosis and therapeutic target for PCa.